Anti-DP treatment after stem cell transplant to prevent relapse
Part of Blood & lymphatic clinical trials.
This early-phase trial tests an anti-DP medicine given after an allogeneic (donor) stem cell transplant. It aims to improve outcomes by targeting immune cells linked to certain transplant match types and reducing relapse risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (AML, ALL, CLL, or certain lymphoma types) and are planning an allogeneic stem cell transplant
- Your tissue type includes DPB1*04:01, and the donor is DPB1*04:01 negative (cord blood has specific matching rules too)
- Your transplant plan uses either donor stem cells from blood (PBSC) or bone marrow (PBSC donor must be able to use G-CSF to collect cells)
- You are 18 to 75 years old, and your cancer was in complete remission or shows enough response before transplant
- You are well enough for study treatment (ECOG 0–2 or Karnofsky score over 60%) and have adequate blood counts
- You must not be pregnant or breastfeeding, and you must agree to contraception if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests two different medicines to prevent graft-versus-host disease (a condition where donor cells attack your body) after a donor lymphocyte infusion. The goal is to make the treatment safer and more effective for patients whose blood cancer has returned after a transplant.
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
This study tests a new way to reduce donor-specific antibodies before a stem cell transplant. It combines standard treatments with an increased infusion of donor cells to help improve transplant success.
Hear when a new Haematologic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.